Let me start with a disclaimer: I am no expert in biological sciences or pharmaceutical companies. Other writers on Seeking Alpha are much more learned in this department than I, and I will leave the industry-specific analysis to them. The following article will focus on a biopharmaceutical company — Bristol-Myers Squibb (BMY) — as a longterm dividend growth opportunity.
The Company
Bristol-Myers Squibb is a $76 billion market-cap biopharmaceutical developer and producer of prescription drugs and specialized treatments for cancer, HIV/AIDS, cardiovascular disease, diabetes, and other diseases. They have made the strategic decision